Business
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
The Harmonic™ clinical trial, a Phase 2 study in never-smoker patients with non-small lung cancer, has activated 5 clinical trial sites, across 12 locations,
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nThe Harmonic™ clinical trial, a Phase 2 study in never-smoker patients with non-small lung cancer, has activated 5 clinical trial sites, across 12 locations, and anticipates multiple additional sites in the US during the 1st half of 2023; first enrolled patients are anticipated for Q2 2023.\n\n\nIND-enabling studies for LP-184 are completed, and submission of the IND application to the FDA is anticipated for April 2023.\n\n\nCompletion of IND-enabling studies for LP-284 and submission of the IND application to the FDA are anticipated in mid-2023.\n\n\nFirst-in-human Phase 1 clinical trials for LP-184, in genomically defined solid tumors, and for LP-284, in multiple non-Hodgkin’s lymphomas, are targeted for launch in mid-2023.\n\n\nStarlight Therapeutics Inc., a wholly-owned Lantern subsidiary, was formed to focus exclusively on the clinical development of therapies for multiple CNS (central nervous system) and brain cancers; clinical trials for lead drug candidate, STAR-001, in CNS cancers are anticipated for late 2023/early 2024.\n\n\nRADR®, Lantern’s oncology-focused AI drug development platform, surpassed 25 billion oncology-focused datapoints; future advancements will include AI-driven insights for the development of combination regimens, including immuno-oncology agents, and for the development of antibody drug conjugates (ADCs).\n\n\n$55.2 million in cash, cash equivalents, and marketable securities as of December 31, 2022.\n\n\nLantern has a cash runway into 2025.\n\n\nConference call scheduled for 4:30 p.m. ET / 1:30 p.m. PT today.\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence (\"AI\") and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.\n\n“The Lantern team spent 2022 focused on preparing our unique drug candidates, LP-184 and LP-284, for the clinic, while at the same time advancing the clinical foundation and infrastructure for our Phase 2 Harmonic™ clinical trial for never-smokers with NSCLC. We have been working relentlessly towards the objective of leading the transformation of our industry’s approach to ...